Phreesia Inc (PHR) valuation
Phreesia P/E ratio history
Phreesia trades at 69.1 times its earnings over the last twelve months and 8.7 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Jan 31, 2026 | $13.43 | $0.04 | 335.8 |
| Jan 31, 2025 | $28.46 | -$1.02 | n/m |
| Jan 31, 2024 | $25.48 | -$2.51 | n/m |
| Jan 31, 2023 | $37.49 | -$3.36 | n/m |
| Jan 31, 2022 | $31.19 | -$2.37 | n/m |
| Jan 31, 2021 | $65.29 | -$0.68 | n/m |
| Jan 31, 2020 | $31.00 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Phreesia valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| PhreesiaPHR | $769M | 69.1 | 8.7 | 1.5 |
| Collegium PharmaceuticalCOLL | $772M | 19.2 | 3.2 | 1.0 |
| Varex ImagingVREX | $776M | 35.4 | 18.2 | 0.9 |
| Beta BionicsBBNX | $754M | — | — | 5.9 |
| AdapthealthAHCO | $790M | — | — | 0.2 |
| ArdelyxARDX | $748M | — | — | 1.7 |
| Cytek BiosciencesCTKB | $792M | — | — | 3.8 |
| OmniabOABI | $741M | — | — | 19.3 |
| OrthopediatricsKIDS | $806M | — | — | 3.1 |
| Peer median | 27.3 | 10.7 | 2.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PHR financials · PHR returns
No forecast, no recommendation. This page describes Phreesia Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.